Hello, everyone, and how are you today? We have now reached the middle of the week, which means, of course, that there is much to do. Meetings and deadlines loom. Phone calls must be made. Projects are on the drawing board. Sound familiar? So let us get started with a delightful cup of stimulation and a big smile. Meanwhile, here are some tidbits. Hope you conquer the world and keep us in mind if you hear something interesting...
Allergan Wins Court Order Blocking Botox Rival (Bloomberg News)
Death Of Elderly Man Magnifies Pradaxa Hemorrhage Concerns (Reuters)
UK Distributor Tied To Fake Avastin Sales (Wall Street Journal)
Gilenya Scrips Slow After Death Reports (Bloomberg News)
More Patients Relapse In Gilead Hepatitis C Trial (Reuters)
Argos Therapeutics Cancels Initial Stock Offering (MedCity News)
Lundbeck Binge Drinking Drug Cut Alcohol Intake In Studies (Bloomberg News)
Lawmakers Tighten Pseudoephedrine Limit In Drug Bill (Charleston Gazette)
Surgery Tops Drugs For Resistant Epilepsy (MedPage Today)
Vertex And Merck Meds Work In HIV Patients (Reuters)
Lilly Tries Again To Remove Poison Pill Provision (Indianapolis Business Journal)
Shire Launches Head-To-Head Study For Vyvanse (Pharma Times)
FDA Approves Discovery Labs Respiratory Drug For Preemies (Associated Press)
Indian Prime Minister Office Examines Drug Pricing (Economic Times)
Hunting For Women In 1983 Antidepressant Trial (Yorkshire Evening Post)
EDITOR'S NOTE: Please check this post for updates throughout the morning